Rare diseases: FDA proposes new system to therapy approvals - Top-Institutions - MDSpire

Rare diseases: FDA proposes new system to therapy approvals

  • By

  • Matthew Perrone

  • February 23, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Children's Hospital of Philadelphia
    Children's Hospital of Philadelphia

    Philadelphia, PA

    Key Differentiators

    • Pediatric Rare Diseases
    • Gene Therapy
    • Translational Medicine

  • #2

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Gene Editing
    • Rare Disease Therapeutics
    • Clinical Trial Innovation

  • #3

    National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS)
    National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS)

    Bethesda, MD

    Key Differentiators

    • Translational Science
    • Rare Disease Research
    • Regulatory Science

  • #4

    Food and Drug Administration (FDA)
    Food and Drug Administration (FDA)

    Silver Spring, MD

    Key Differentiators

    • Regulatory Science
    • Rare Disease Drug Approval
    • Gene Therapy Oversight

  • #5

    Massachusetts General Hospital (MGH) - Center for Genomic Medicine
    Massachusetts General Hospital (MGH) - Center for Genomic Medicine

    Boston, MA

    Key Differentiators

    • Genomic Medicine
    • Rare Disease Therapeutics
    • Gene Editing

Original Source(s)

Rare diseases: FDA proposes new system to therapy approvals

  • by Matthew Perrone

  • February 23, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Dupilumab Faces Trial in Chronic Hives

Phase III CUPID-C trial evaluates biologic therapy in patients with chronic spontaneous urticaria uncontrolled by antihistamines.

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.